Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OCU 200

Next Previous
X
Search
Drug Profile

OCU 200

Alternative Names: OCU-200; Transferrin-Tumstatin

Latest Information Update: 27 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Colorado at Anschutz Medical Campus
  • Developer Ocugen
  • Class Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Integrin alphaVbeta3 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetic macular oedema
  • No development reported Diabetic retinopathy; Wet age-related macular degeneration

Most Recent Events

  • 16 Jan 2025 Phase-I clinical trials in Diabetic macular oedema in USA (Intravitreous) (NCT05802329)
  • 28 Nov 2024 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in USA (Intravitreous)
  • 28 Nov 2024 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA (Intravitreous)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top